ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

COS Collagen Solutions Plc

6.625
0.00 (0.00%)
18 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Collagen Solutions Plc LSE:COS London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.625 6.25 7.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Collagen Solutions Share Discussion Threads

Showing 401 to 424 of 850 messages
Chat Pages: Latest  22  21  20  19  18  17  16  15  14  13  12  11  Older
DateSubjectAuthorDiscuss
06/1/2016
12:51
It's for these reasons you have listed there that I'm not selling, jacobjohn.
doodlebug4
06/1/2016
10:00
what we might see very shortly....

1. news on the progress of a separate production facility to service one companies collagen requirements only...
2. News of progress to find a partner for taking collagen solutions to the chinese market.
3. News on supply deal with a global blue chip medical device maker.
4. News on progress of COS' own medical device for knee operations.
5. General additional supply agreements with medical companies.

This is quite a pipeline... and not hot air based on real proven growth in revenues, and reduction in costs experienced in first half interim results.

jacobjohn7
06/1/2016
09:46
Hi, yeah likewise for me..
but there is pipeline of several different newsflow potentials due.. which will give us the traction and revenue growth to keep this story flowing..
only thing we dont have at mo is shareholder value.. unless buying in at this point..
Ah well, just as waiting game.. come on cos... get 2016 off to a cracking start...;o)

jacobjohn7
05/1/2016
14:54
jacobjohn, I've just noticed your message on Money*m - sorry I don't post on that forum anymore. Anyway I just keep taking my daily dose of patience pills here, I still believe in the company and the product etc. - everything seems to be ok, but the share price is going nowhere. I'm going to stick with it in the meantime, but we do seem to be in a state of torpor here.:-)
doodlebug4
24/12/2015
10:19
Interesting article from the science point of view with regards what collagen solutions are tapping in to..

hxxp://phys.org/news/2014-06-materials-scientists-collagen.html

jacobjohn7
16/12/2015
23:34
Deffo manipulated. .. very strange. They have it on aleash .. one day it won't be restrained. It was walked down with absolutely nothing volume, weve had mostvolume in its history and excellent newsflow and it flatlines. Very uneven playing field.
jacobjohn7
16/12/2015
21:14
I can't figure this out either jacobjohn, you do think the share price should be higher - for various reasons. I posted a news item on another thread today which outlined some possible re-vamping of share trading systems in the US and if implemented it would cut out market manipulation and short trading malpractice. We need the same thing to happen in this country.
doodlebug4
16/12/2015
20:45
Are we being held back? Increased volume, mainly buys, l&g reduced granted... good interims, good prospects, visible pipeline, director confidence... but still languishing 9p mark? Any thoughts and opinions please.. personally think the l&g sell order still going out as sells at the level initiated. , dont know fully the trading practice of the market makers.. but should imagine movement once that has cleared..
jacobjohn7
09/12/2015
08:29
Collagen Solutions PLC Hardman Issues Research Report
09/12/2015 7:00am

RNS Non-Regulatory


TIDMCOS

Collagen Solutions PLC

09 December 2015

Hardman & Co issues research report on Collagen Solutions

Solid interim results: First half results to 30(th) September demonstrate clear progress against the Board's objective of creating a business with at least a GBP100m valuation by 2020. Proforma sales growth of 97%, driven by new customer contract wins and by pipeline progress from existing customers' medical device programmes. The potential for operations in China (via joint venture) and the development of a new production facility for a global device manufacturer are both in late stage discussions which would underpin longer term growth, if successfully executed. The long term pipeline continues to build with strategic collaborations.

Please click here for the full report:

doodlebug4
07/12/2015
10:17
Another rolling revenue boost... well done :-)
jacobjohn7
07/12/2015
10:04
Collagen Solutions PLC Collagen Solutions Supply Agreement with BBI07/12/2015 7:00am

TIDMCOS

Collagen Solutions PLC

07 December 2015

Collagen Solutions Plc

(the "Company" or the "Group")

Supply agreement with BBI Solutions

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces the execution of a supply agreement between Collagen Solutions (UK) Ltd and BBI Solutions OEM Limited ("BBI").

The supply agreement which will be for an initial three year period and on a rolling annual basis thereafter, will encompass the supply of Collagen Solutions' medical grade materials to support the research, pre-clinical and clinical development programmes of BBI's broad customer base.

Commenting on the agreement, Dr Stewart White, CEO of Collagen Solutions, said: "BBI has a renowned reputation for their knowledge in the reagent supply, diagnostics and development space and are therefore an excellent partner to enable collagen users to access our high quality medical grade GMP approved materials. We are very pleased to be working with Lyn and the team in Cardiff."

Lyn Rees, CEO of BBI Solutions added: "Our mission is to deliver exceptional products and technologies through innovation, partnership, effective delivery and collaboration. By working alongside the team at Collagen Solutions we can build on our expertise and reputation for supplying critical biological products into regulated markets. Our developing customer base in the advanced cellular and regenerative medicine markets are increasingly looking for collagen compounds. As a result, it was important for us to find a partner who can supply the high grade collagen they require consistently. Through this relationship with Collagen Solutions, we can continue to build our brand, improve the quality of people's lives and further our goals for the future in this transformational area of healthcare.

jacobjohn7
04/12/2015
19:41
Another decent buying volume day. Hopefully bit of press coverage this weekend, regardless this will go its own way ..currently bit under the radar of most
jacobjohn7
02/12/2015
19:47
Deals keep Collagen Solutions on track for market cap target

17:04 02 Dec 2015

Firm aims to expand regenerative medicine and in-vitro diagnostics business

Collagen Solutions makes and supplies collagen products for medical uses

Collagen Solutions (LON:COS) is targeting a £100mln market cap in five years – and it reckons deals this year and next year will keep it firmly on track to achieve that.

The company, which makes and supplies collagen products for medical uses, is aiming to build on its medical device business with forays into regenerative medicine and in-vitro diagnostics.

It passed a key milestone on that journey this year by striking a supply deal with Nasdaq-listed musculo-skeletal specialist Histogenics Corp (NASDAQ:HSGX).

A couple of days before, the group bought assets and an exclusive worldwide intellectual property licence for collagen-based cartilage and bone implant ChondroMimetic from Orthomimetics and Cambridge Enterprise. The implant's potential market is worth more than US$500mln.

The group is now talking to potential partners and customers on several different continents about more deals.

It says it should be able to say more on progress as soon as early next year, provided all goes well.

The group, which had revenue of just under £1mln in the year to July, is targeting £3.7mln this year, rising to £16mln-20mln by 2020.

It expects underlying earnings that year to be between £8mln and £10mln, against an underlying operating loss in 2014/15 of about £845,000.

Hitting a market capitalisation of about £100mln by 2020 from its current valuation of about £15.4mln may sound like a big ask – but chief executive Stewart White is confident of doing it.

White said: “We think this is a realistic and challenging goal in terms of the potential that this business has.”

Significant interest

Most commonly found in the skin, collagen is the structural protein that supports various connective tissues.

Versions of collagen can be human-derived, but more commonly, for medical use, they are taken from animals such as cows, pigs, chicken and even fish.

Collagen tends to be used in wound care – burns and skin grafts – prosthetic veins and arteries, bone grafts and skin regeneration.

The company itself provides products in various forms, ranging from raw tissue and tissue scaffolds to soluble and powdered collagen.

The merger of Collbio and Collagen Solutions LLC in the UK and US, respectively, created a business capable of manufacturing, research, sales and marketing.

The addition of New Zealand’s Southern Lights Biomaterials last December gave it processing capacity as well as a customer ;base in Asia, meaning the business is in three major continents.

Collagen Solutions’ has a big dentistry customer in South Korea and White and his colleagues have just completed a trip to Japan which attracted significant interest.

Crucially, the company is in the process of finding a partner to establish a presence in China.

And it is in talks with a well-known global blue-chip medical device maker about a deal to supply the latter with collagen in New Zealand for onward processing. White said he hopes to update on that early next year.

“We have put together that proposal just this week and if we get agreement to go ahead with it, we’ll inform the market accordingly,” he said.

Dramatically under-valued

Collagen for medical devices currently contributes more than 80% of the company’s revenue.

But it hopes regenerative medicine and research diagnostics will each contribute a third of revenue within five years, with medical devices making up the rest.

The goals White has set for the business may sound challenging, but he says they are driven by the market and customers.

Shares in the group were worth 9p in afternoon London trading on Wednesday.

“We believe we’re dramatically under-valued,” White said. “We think we’ve got it all to play for.”

In half-year results this week, Collagen posted a 36% fall in losses to about £357,000 on a 920% rise in revenue to £1.5mln in the six months to September 30. Net cash fell to £3.1mln from about £3.4mln in March.

Broker Hardman & Co said in a note after the company's full-year results in July that Collagen was showing clear evidence of meaningful gross margins (78%) and new customer wins.

Anticipated higher sales volumes should begin to offset central overheads of about £1.5mln, with cash flow break-even anticipated in the second half of 2015/16.

"These margins, in turn, are expected to drive long term shareholder value," the broker said.

jacobjohn7
02/12/2015
19:40
Excellent article with some decent information of revenue growth...
jacobjohn7
02/12/2015
19:24
Called it..wouldnt be surprised to see another director buy rns tomorrow or it would e nice ... this is a good sign of things rapidly coming together at collegan solutions... not so distant future for chinese partnership potentially.
interesting stuff on the horizon

jacobjohn7
02/12/2015
16:05
02/12/2015 3:48pm

UK Regulatory (RNS & others)


Collagen Sol (LSE:COS)
Intraday Stock Chart
Today : Wednesday 2 December 2015


TIDMCOS

RNS Number : 7861H

Collagen Solutions PLC

02 December 2015

Collagen Solutions Plc

(the "Company" or the "Group")

Director/PDMR Shareholding

The Board of Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative is pleased to announce that Mr. Malcolm Gillies, Non-Executive Director of the Company, has today purchased 438,714 ordinary shares in the Company at 9p per share.

Following this transaction, Mr. Gillies total beneficial holding has increased to 1,653,000 ordinary shares representing 0.96 per cent of the issued ordinary share capital of the Company.

doodlebug4
02/12/2015
14:08
well weve had 500k definite buys in last 2 days. buy price is under mid price just at mo.
jacobjohn7
02/12/2015
14:05
We need something to get us moving --- and preferably in an upwards direction.:-)
doodlebug4
02/12/2015
13:52
partnership for chinese market will get us moving... and revenue streams ;o)
jacobjohn7
02/12/2015
13:49
".. hopefully it is something we will be able to update on in the not too distant future,” Dr Stewart White
jacobjohn7
02/12/2015
13:48
Collagen Solutions eyes China market as sales rise

PERRY GOURLEY
21:00Tuesday 01 December 2015

Scottish life sciences company Collagen Solutions yesterday said it was looking at opportunities to move into the Chinese market as it posted a major rise in sales and narrowed losses.

The Glasgow-based business, which specialises in providing medical grade collagen for use in regenerative medicine and medical devices, saw sales rise to £1.46 million in the six months to the end of September compared to £143,213 in the same period last year. Pre-tax losses narrowed to £356,537 from £560,831.

Collagen Solutions said it was exploring the possibility of breaking into China on the back of the growth it was seeing in its existing markets

“As a small AIM company we would need to partner with someone to do that but hopefully it is something we will be able to update on in the not too distant future,” Dr Stewart White, the chief executive, said.

Growth in sales during the year was helped by the contribution of Southern Lights Biomaterials in New Zealand which it acquired last year.

The company has also recently acquired intellectual property rights for ChondroMimetic, a collagen-based implant for treatment of bone defects, and believes the potential opportunity warrants a separate management team.

Collagen Solutions has set a target that by 2020 it will be a £100m business – compared to today’s market cap of around £15m – and White said the latest figures highlighted progress towards that goal. “If you look at peer companies and their valuations I think we compare very well in terms of the potential we have, the market for our products and our team.”

Read more:

jacobjohn7
01/12/2015
14:10
someone else had a bigger nibble ;o)
jacobjohn7
01/12/2015
13:40
had a nibble..
jacobjohn7
01/12/2015
13:31
IMO we should see steady movement upwards from now on... certainly looking more of a viable play for investors.
jacobjohn7
Chat Pages: Latest  22  21  20  19  18  17  16  15  14  13  12  11  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com